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Abstract
The effects of BMP2 on bone marrow stromal cell differentiation and bone formation after bone
marrow ablation were determined using C57 BL/6J (B6) mice. Inhibition of BMP2 expression with
lentiviral BMP2 shRNA prevented both mineralized nodule formation in vitro and bone formation
in vivo, and blocked the expression of Runx2 and osterix, transcriptional determinants of terminal
osteogenic differentiation. No effect was observed on the expression of Sox9, a transcription factor,
which is the one of the first transcriptional determinant to be expressed in committed
chondroprogenitor and osteoprogenitor cells. In vitro studies showed that exogenously added BMP7
rescued the expression of osterix and enhanced the expression of Sox9, but had no effect on the
expression of Runx2, while it only partially recovered the development of mineral deposition in the
cultures. On the other hand, the exogenous addition of BMP2 rescued both Runx2 and osterix
expression, did not enhance the expression of Sox9, but fully recovered the inhibition of mineral
deposition in the cultures. Using antibodies against CD146 and Sox9, immunohistological
examination of the cell populations found in the medullary space three days after bone marrow
ablation, showed qualitatively equal numbers of cells expressing these skeletal progenitor and stem
cell markers in control and BMP2 shRNA-treated animals. Fluorescence Activated Cell Sorting
(FACS) analysis of the cells found with the marrow cavities at three days after marrow ablation using
CD146 antibody showed near equal numbers of immunopositive cells in both control and shRNA
treated animals. In summary, the differences observed in vitro for BMP2 and BMP7 on osteogenic
gene expression and mineralization suggest that they have differing effects on bone cell
differentiation. These results further demonstrate that in vivo BMP2 is a central morphogenetic
regulator of post natal osteoprogenitor differentiation, but does not affect recruitment of progenitors
to the osteoblastic lineage.
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Introduction
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β (TGF-
β) superfamily of proteins that have diverse effects on cells of the mesenchymal lineage.
Several BMPs have been shown to promote chondrogenic and osteogenic differentiation of
mesenchymal stem cells in vitro, and bone formation and repair in vivo [1-3]. Studies using
non-targeted gene ablation of specific BMPs have shown that several of these molecules play
diverse biological roles during organogenesis [4]. Global ablation of BMPs 2 and 4 lead to
early embryonic lethality, while the loss of other BMPs produce less severe phenotypes and
affect later stages of embryogenesis or postnatal development of various tissues [5-7]. Specific
studies on the molecular functions of BMPs have shown that these factors regulate
proliferation, differentiation, and apoptosis in diverse cell types [8-11]. The role of BMPs in
skeletal tissues has been more specifically examined by the removal or expression of functional
mutations of various BMP receptors in only skeletal cell lineages. Other approaches have used
the selective overexpression of the BMP antagonist noggin in cartilage or bone. Using murine
transgenic models, the targeted disruption in osteoblasts of either BMP receptor type IA or the
expression of a dominant-negative BMP receptor type IB were found to both impair osteoblast
function and reduce bone volume [12,13]. Other studies in which noggin was overexpressed
in actively growing osteoblasts by using the bone specific segment of the Col1a1 promoter to
drive its expression led to increased bone volume that was associated with a decreased rate of
bone formation. This apparent paradox was related to reduced periosteal bone formation
accompanied by reduced resorption of bone in the marrow spaces, and led to an increase in the
volume of intramedullary bone. Overexpression of noggin also decreased osteoclast number
and resorption suggesting that BMPs play an important role in calibrating coupled remodeling
[14]. In contrast, when noggin overexpression was restricted to mature osteoblasts by placing
it under the control of the osteocalcin promoter, a generalized severe osteopenia developed
[15]. These different sets of results suggest that there is a complexity to BMP function that
may be related to how these molecules affect different stages of osteogenic lineage
development and lead to different effects on the remodeling of cortical and intramedullary
bone.
A previous study from our laboratory has shown that osteogenic differentiation of bone marrow
stromal cells is associated with the expression of multiple BMPs and that inhibition of BMP
expression by either noggin or BMP2 antibody blockade prevents osteogenic differentiation
[16]. In a recent study by Tsuji et al. [17], inactivation of BMP2 in limb bud mesenchymal
tissues, before the onset of skeletal development, lead to the inability to repair post natal
fractures. Interestingly, the loss of BMP2 in mouse limb bud mesenchymal tissues did not
affect normal pattern formation of skeletal tissues or embryonic limb development. These
results suggest that BMP2 plays a central role in post natal bone growth and repair.
Studies from our laboratory have shown that there is a coordinated expression of multiple
BMPs and their receptors during fracture healing and during the in vitro osteogenic
differentiation of bone marrow stromal cells [16,18]. Furthermore, BMP2 appears to regulate
the autogenous expression of a number of other BMPs, and the osteogenic differentiation of it
is associated with the increased expression of certain BMPs and the down regulation of others.
Indeed, the in vivo efficacy of a given BMP’s activity might relate to the target population of
cells that is most responsive to it. In this regard, it is generally thought that BMPs mediate stem
cell recruitment and, as such, would be beneficial in attracting cells to the osteogenic lineage
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in the setting of skeletal repair. However, there has been little research to identify those stages
in the progression of the skeletogenic lineage in which a given BMP will show the greatest
efficacy of action in promoting osteogenic differentiation. There have also been few studies
done to discriminate one BMP’s activity from another at a molecular level or to understand
how multiple BMPs might work together to promote optimal healing.
In the studies presented here, a lentivirus that expressed BMP2 shRNA was employed to
selectively inhibit only BMP2 mRNA expression during bone marrow stromal cell
differentiation in vitro. To study the function of BMP2 in vivo, a bone marrow ablation model
was used. In this in vivo model, robust intramembranous bone formation is induced by
surgically reaming out the medullary space [20] and BMP2 expression was blocked after
reaming by injecting into the marrow cavity the same BMP2 shRNA lentiviruses as used in
vitro. Within the context of these studies, a comparison of the selective effects of the exogenous
delivery of BMP2 or BMP7 on phenotype rescue in relation to the selective loss of BMP2
expression was also performed. This approach allowed us to determine if different BMP
isotypes have comparable effects on osteogenic differentiation. Finally, these studies were
designed to specifically identify those transcription factors that mediate the actions of BMPs
and the specific stage in the osteogenic lineage at which these BMPs act to promote cell
differentiation.
Materials and Methods
Cell Culture and Osteoinduction
Research was conducted in conformity with all Federal and USDA guidelines under an IACUC
approved protocol. All cell culture studies were conducted with C57 BL/6J (B6) male mice of
8-10 weeks of age (Jackson Laboratories, Bar Harbor, ME), while the marrow ablation studies
used 15 week old male mice. Primary bone marrow stromal cell cultures were prepared and
osteogenesis was induced as previously reported [16]. Phenotype rescue experiments were
performed by supplementing the osteoinductive media with 200ng/ml BMP7 or BMP2 protein.
All experiments were performed with 3 separate cell preparations and all measurements from
a given set of cells preparations were carried out with three replicates.
In Vitro Assay of Osteogenesis
Alkaline phoshatase (APase) activity was assayed using CSPD chemiluminescence substrate
with sapphire 2 enhancer from the cell culture media. The change in alkaline phoshatase activity
per minute was recorded with a luminometer. Alizarin red staining and osteogenesis
quantification were performed by using a standard osteogenesis quantification kit (Millipore
Billerica, MA). Nodule counting was as described by Edgar et al., 2007 [16].
Surgical Marrow Ablation
Tibia marrow ablation was performed as described by Suva [19] and modified by Gerstenfeld
[20] for mice. Briefly, fifteen-week-old C57 BL/6J male mice with weights between 30-35
grams were used for this study using the same approach. Animals were anesthetized with 4%
isoflurane, and their right hind legs were shaved and prepped with betadine solution. A
longitudinal incision through the skin was made over the knee, and the medial half of the
patellar tendon was incised to expose the joint. With the knee in maximal flexion, a 0.5 inch
25 gauge needle was used to create a starting portal centromedially in the tibial plateau. A 30
gauge needle was next inserted to find the path of the medullary space extending to the level
of the middiaphyseal bow. Sequential reaming of the tibial canal was then performed using 27,
25, and 23 gauge needles respectively. The medullary cavity was flushed with 200 μl of sterile
PBS, and the bone marrow contents were aspirated with a 27 gauge needle and syringe. To
prevent backflow, a unicortical hole was created just distal to the bow of the tibia using a 0.5
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inch 25 gauge needle. An intramedullary injection of 50 μl of saline (control), or various
solutions of lentiviral particles was performed via a 30 gauge needle and syringe. The skin was
closed in a single layer fashion using 4-0 vicryl suture. Animals were permitted immediate
weight bearing as tolerated.
Micro Computer Assisted Tomography (μCT)
Specimens were scanned at a resolution of 16 μm using a Scanco μCT 40 system (Scanco
Medical, Basserdorf, Switzerland). For these measurements, a region of interest (ROI) was
defined for each of the experimental sample groups in the longitudinal axis by assessing a fixed
distance from the proximal growth plate. This was established by taking 100 slices distal from
this point of reference. Only intratrabecular bone was determined based on manual substraction
of the surrounding cortical bone. The measurements were done as reported earlier [21]. Total
Bone volume and average mineral density were each compared across groups using a Kruskal-
Wallis test (analysis of variance by ranks) [22].
Demineralized Histology and Immunohistochemistry
For histological assessment, the tibiae were fixed, decalcified, sectioned, and stained as
previously described [23]. Serial sections were generated and slides were taken every 100
μM. Slides were stained with hematoxylin and eosin. Similar immunohistological procedures
to those that we used previously were carried in this study [21]. Polyclonal antibodies to CD146
polyclonal and Sox9 antibody were from Abcam. Mice that were injected with lentiviruses
expressing β -Galactosidase were reacted with X-gal using a modification of the procedure
reported by Mortlock et al [24]. Briefly, at the time of euthanasia the tibiae were directly
collected into 4% paraformaldehyde and fixed overnight at 4°C. After fixation the tibiae were
cut in half in the longitudinal plane with a scalpel blade and then rinsed 3-4 times for 30 min
in wash buffer and stained in wash/staining buffer with 0.8 mg/mL X-gal for 24 h. Stained
tibiae were rinsed several times in PBS and whole bones were digitally photographed.
Lentivirus Preparation
All work with lentiviruses was performed under BL2 conditions. All lentivirus based shRNA
DNA clones and packaging cell lines that were used for making the viral transduction particles
were from Sigma-Aldrich Inc., St. Louis, MO, USA. The lentiviral constructs expressing β-
Galactosidase was generated in the laboratory of Dr. Inder Verma and was available from
Addgene, Cambridge, MA, USA (plasmid 12108), while viral DNA plasmid containing the
luciferase (pHR’EF1a-luciferase/WPRE-SIN) was kindly provided by Dr. Jeffrey Medin,
University Health Network, Toronto, Ontario, Canada. Lentivirus particles were prepared
using three-plasmid system from Addgene (http://www.addgene.org/pgvec1). In short, 293T
cells were plated at density 2 × 106 293T cells in 10cm2 dishes containing 10 mL of media.
After 24 hrs, the cells were overlaid with complex containing 3 plasmid system (PLKO shRNA,
pCMV-VSV-G, and pCMV-dR8.2 dvpr) at the ratio 8:1:8 using Fugene 6. The supernatant
was collected starting from 48 to 96 hrs post-transfection. The virus particles were concentrated
by ultracentrifugation at 18,500 rpm for 1 hr 30 min with Beckman ultracentrifuge using SW28
rotor, resuspended in PBS and stored until use at -70°C. The physical titer of virus particles
were determined by using p24 ELISA (Cell Biolabs, Inc San Diego, CA).
Lentivirus Particle Transduction
Experiments performed in bone marrow stromal cells were carried out in adherent cultures at
10 days after they had been isolated. At this time, the cells had been grown in osteoinductive
media for four days. Viral transduction was performed in media containing 8 μg/ml
hexadimethrine bromide for 12 hrs, at which time this media was replaced with osteoinductive
media alone. The media was changed every 48 hrs thereafter with fresh osteoinductive media.
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Intra-tibial injection of lentivirus particles was carried out after surgical marrow ablation. After
ablation, the cavity was washed three times with PBS containing 0.0032% polybrene in order
to increase the transduction efficiency of the lentivirus. After the final wash, either 50 μl of
PBS or 50 μl lentivirus 2 × 106 viral particles that contained coding sequences for either lacZ
(LV-lacZ), luciferease (LV-Luc), a non target shRNA (NT), or shBMP2 were injected along
with polybrene at a final concentration of 8μg/ml in PBS and the incision was closed. The
animals were monitored for a week and tibias were removed at day 7 and either fixed and used
for histological and micro-CT analysis or flash frozen in liquid nitrogen and used for RNA
preparation.
Bioluminescent imaging of tibia in vivo
A subset of mice were imaged using an IVIS 200 system (Xenogen, Alameda, CA,
USA). Anesthesia was administered in an induction chamber with 2.5% isoflurane in
100% oxygen at a flow rate of 1 L/min and maintained while the animal was in the
IVIS imaging device with a 1.5% mixture at 0.5 L/min. Approximately, 150 μl of D-
luciferin (30mg/ml dissolved in PBS was injected intraperitoneally. Bioluminescent
images were taken from 1 min to 45 min and peak signals were observed around 20
min. The data are reported as the photon flux (p/s) from a defined region of interest
in tibia of lentivirus expressing luciferase compared to noninjected control mice.
Isolation of mRNA and Molecular Biology Procedures
Tissues were collected and RNA was processed as previously described [25]. Messenger RNA
levels were assessed by qRT-PCR as previously described [21,26].
Flow cytometry
Cell populations were prepared from the medullary space as described above from N = 3
animals per experimental group and repeated at least three times. Cells were stained as reported
for CD146 [27]. Briefly, CD146 flow cytometry was performed by using CD146-PE
monoclonal antibody or PE Mouse IgG1, k Isotype control (BD Bioscience, Bedford, MA).
MSCs prepared as mentioned earlier, plated for overnight, trypsinsed next day, and stained
with CD146-PE antibody for 30 min on ice. The cells were sorted by using a MoFlo instrument
(Dako, Carpinteria, CA 93013). The data were analyzed by using SUMMIT software (Cytomation,
DakoCytomation, Inc., Fort Collins, CO). All the experiments were repeated 2-3 times for each
group. The sorted CD146 cells were plated in 6-well plate for reconfirmation of the
osteoprogenitor population.
Results
Establishment of Bone Marrow Stromal Cell Transduction of VSV-G Pseudotyped Lentivirus
Particles
Initial studies were focused on defining the optimal conditions of lentiviral transduction of
bone marrow stromal cells and evaluated both the effect of lentivirus on cell viability and on
the normal osteogenic development of bone marrow stromal cells. A lentivirus that expressed
green fluorescent protein was first used to determine whether the marrow stromal cells could
be efficiently transduced. Increasing numbers of cells were shown to take up the virus from a
multiplicity of infection (MOI) of 10-100 with the optimal numbers of viable cells taking up
the virus seen at an MOI of 30 (Fig. 1A). These data were validated by FACs analysis of
numbers of viable cells in the transduced cultures which showed that a transfection efficiency
of ∼75-95% was achieved (data not shown). Using a virus containing a nonsense sequence that
was not targeted (NT) to any specific mRNA as a control, the long term viability of the MSCs
cultures were tested after transduction, using lactate dehydrogenase activity assay. These data
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showed that the virally transduced marrow stromal cell cultures had identical long term
viability as the control cultures at an MOI of 30 (Fig. 1B). The effect of viral transduction on
terminal osteogenic differentiation was next assessed by examining the number of osteogenic
nodules that formed in the MSCs in the presence and absence of non targeted (NT) virus. As
can be seen in these studies, the number of nodules remained the same demonstrating that the
lentivirus by itself had no adverse effect on osteogenic development (Fig. 1C).
In the next series of studies, a group of five different shRNAs for BMP2 were screened to
identify the one that was most efficient at inhibiting the expression of BMP2 mRNA. Groups
of cell cultures were individually transduced with the separate lentiviruses for three shRNAs
that were directed towards BMP2 at day 10, which was 8 days prior to peak BMP2 expression
during the osteogenic differentiation of these cultures [16]. Three separate means of assessing
the inhibitory activities of each of these shRNAs were examined. First, each of the shRNAs
was tested for their ability to block the expression of BMP2 mRNA expression. Each of the
shRNAs showed differing effects with the 878 sequence demonstrating ∼80-90% knock down
in BMP2 mRNA expression. Since our previous antibody blockade studies had suggested that
the osteogenic differentiation of the marrow stromal cell cultures were dependent on the
autogenous expression of BMP2 expression, the functional consequences on osteogenic
differentiation of each of BMP2 shRNAs was next examined. Two separate phenotypic
markers of osteogenic differentiation osteocalcin expression and alkaline phosphatase (APase)
activity were examined (Fig. 1E and 1F). Each clone showed consistent inhibition on these
two functions that were relatable to the levels of knock down of the expression of BMP2 mRNA
expression. Thus, clone 878 showed the greatest down regulation of BMP2, osteocalcin mRNA
expression, and APase activity, which was statistically significant in comparison to the non
targeted virus treated cultures. All subsequent experiments that were performed were then
carried out using this clone.
BMP2 Knock Down Can Be Rescued by Administration of Exogenous BMP-7 Protein
Cultures that had been transduced with the sh-BMP2 virus were treated with BMP7 in order
to assess if the osteogenic differentiation of the marrow stromal cell cultures were selectively
dependent on BMP2 expression or if BMP7 was capable of serving a redundant function and
would rescue cellular differentiation. It is important to note that marrow stromal cells do not
express any observable mRNA for BMP7 [16] therefore allowing for the definitive assessment
of its sole function in this culture model system. The levels of expression of BMP2 were first
determined across the time course of marrow stromal cell osteogenic differentiation (Fig. 2A).
Under normal differentiation conditions BMP2 mRNAs showed increasing expression until
16 days in culture, after which they began to fall. BMP7 treatment alone in the absence of
BMP2 shRNA increased expression of BMP2, however the exogenous treatment of BMP7 did
not have any effect on BMP2 expression in the BMP2 shRNA treated cultures, thereby showing
the overall efficacy and persistence of the shRNA inhibition of the BMP2 expression in these
cultures. Examination of the levels of APase activity showed that BMP7 alone would increase
the overall levels of APase activity in the NT lentivirus transfected cultures indicating that the
lentiviral transfection did not interfere with BMP7 signaling. The transfection of the BMP2
shRNA downregulated APase activity while treatment with BMP7 recovered the APase
activity to that in NT controls (Fig. 2C).
An examination of the accumulation of nodules and mineral contents in BMP7 and shRNA
treated cultures (Fig. 2D-2F) showed that the exogenous addition of BMP7 by itself increased
the total mineral accumulation in the culture but did not have an over effect on the number of
nodules. The exogenous treatment of the cultures with BMP7 while fully recovering the number
of nodules in the BMP2 shRNA treated cultures, did not fully rescue the accumulation of the
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total Ca that was observed in the BMP2 shRNA treated cultures, which only reached a third
that of the NT treated cultures (Fig. 2D-2F).
The molecular mechanisms by which BMP2 regulated osteogenic differentiation within the
marrow stromal cell cultures were examined by assessing the expression of mRNAs that encode
four transcription factors known to control skeletal progenitor differentiation into osteogenic
cells (Fig. 3). These transcription factors are: SOX 9, which commits stem cells to the skeletal
lineage and is common to both chondrogenic and osteogenic cells; Osterix, which directs the
lineage commitment to osteogenesis; RunX2, which is involved in both terminal differentiation
and promotes the development of phenotypic characteristics that promote mineralization of
osteoid matrix [28]; and Msx2 which is found in proliferating but not fully differentiated
osteogenic cells [29]. The temporal expression of each of these transcription factors was first
assessed over the time course of the differentiation of the marrow stromal cultures (Fig. 3, left
panels). These results may be compared to the end point measurements of each of these mRNAs
in cultures treated with both exogenous BMP7, sh-BMP2 inhibition of BMP2 expression, and
rescue of BMP2 inhibition with BMP7 treatment (Fig. 3, right panels).
Under normal growth conditions that promoted the osteogenic differentiation, the expression
of Runx2 and osterix both showed increasing expression until day 16 after which their peak
levels decreased. In contrast, Sox9 showed a transient increase at day 10 after which the levels
decreased. Interestingly, the expression of Sox9 showed a very sharp increase at the end of
culture period at day 21. Msx2 expression levels had a distinct peak at day 14, after which they
fell throughout the remainder of the culture period. With the exception of Runx2, Sox9, osterix,
and Msx2 all showed increased expression when the cultures were treated with BMP7.
Inhibition of BMP2 expression decreased the expression of Runx2 and osterix, while having
no effect the expression of Sox9 and Msx2. It is interesting to note that BMP7 when added to
the BMP2 shRNA treated cultures, the expression of all of the transcription factors but Runx2
were returned to their pre-inhibition levels or as in the case of Sox9 and Msx2 even greater
levels than those seen in the NT control cultures.
Rescue of BMP2 Knockdown Cultures by Administration of Exogenous BMP2 Shows Unique
Differences from Rescue with BMP7
The rescue of the osteogenic phenotype with the exogenous addition of BMP7 did not
completely recover the expression of either Runx2 or mineralization of the cultures, suggesting
that the signaling processes that are mediated by BMP7 are in some manner different from
those of BMP2. Possible explanations for these observations might be due to differences in
this BMPs interaction with the available receptors on the marrow stromal cells and/or signal
transduction processes that are mediated by BMP7 in comparison to BMP2. Alternatively,
lentiviral transduction of the cells might interfere with the biological activities that are mediated
by exogenously administered BMPs. In order to further examine these possibilities, cultures
that had been transduced with lentiviral containing BMP2 shRNAs were treated with
exogenously added BMP2. These results are shown in Fig. 4. Exogenous addition of BMP2
protein was not able to increase the expression of BMP2 mRNA expression that has been
inhibited by the shRNA to BMP2. Comparisons of the effects of exogenous BMP2 treatment
on the development of nodules and the overall mineralization of the cultures between the BMP2
and BMP7 show that BMP2 increased the number of nodules by about 50% over the NT treated
cultures and fully restored mineral deposition. Like the exogenous addition of BMP7, the
exogenous addition of BMP2 increased above control levels the expression of osterix, but more
importantly the Runx2 expression was almost completely restored to its control levels. It is
noteworthy that Sox9 levels were not increased to the same extent that was seen with BMP7
treatment while Msx2 were only slightly elevated.
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Central Role of BMP-2 in Injury Induced Post Natal Bone Formation
In order to asses the role of BMP2 during osteogenic differentiation in vivo, a model of surgical
marrow ablation was used to induce intramedullary bone formation. Two separate control
experiments were carried out to assess both the uniformity of lentiviral infection within the
developing bone tissues after their introduction into the medullary space at the time of surgery,
and the persistence of lentiviral expression within these tissues. In order to assess the uniformity
of the viral transduction gross staining of the bone tissue was carried out in tissues infected
with a lentivirus expressing the β-galactosidase gene. Varying degrees of LacZ staining was
seen at both time points within all six of the bones that were examined. Five out of the six
specimens showed very intense reactions either in, throughout the medullary space, or on the
endosteal lining surfaces of the cortical regions of the bone. Equal intensity was also seen for
the LacZ staining at both day three and seven after the intramedullary reaming and introduction
of the virus into the tissues (Fig. 5A). A quantitative assessment of the persistence of lentiviral
gene expression was made by measuring the luciferase expression in vivo over the same 7 day
period after transduction, which showed that the intensity of luciferase activity increased until
day 7 (Fig. 5B). The effect of knockdown of BMP2 expression in vivo, during bone formation
after marrow ablation is presented in Fig. 5C and 5D. MicroCT analysis (Fig. 5C) of the newly
formed bone tissues showed robust osteogenesis in the saline injected groups after seven days.
Injection of the non targeted lentivirus into the marrow space after ablation caused some
reduction in new formation however this was significantly less than that seen in the BMP2
shRNA samples. Injection of BMP2 shRNA lentivirus caused a statistically significant
decrease in the formation of mineralized bone tissue compared to either the NT lentivirus or
the control PBS injections. The effect of BMP2 shRNA lentivirus on the unmineralized tissues
and cells that were recruited into the medullary space after seven days, are seen in Fig. 5D.
The histological analysis confirmed the microCT analysis, with the control and NT virus treated
animals showing the development of an extensive network of trabeculated bone with islands
of hematopoietic and myeloid tissues forming between the trabeculea. In contrast, the BMP2
shRNA lentivirus treated animals showed a large number of fibroblastic cells filling the
medullary space with little evidence of condensation of these cells into trabecular structures.
Interestingly, in the absence of bone formation there also appeared to be no evidence that large
amounts of hematopoietic and myeloid tissues had formed either.
In order to assess the underlying effect of the inhibition of BMP2 expression on the in vivo
differentiation of osteogenic cells after the surgically induced bone formation, the same panel
of transcription factors were assayed as were examined in the marrow stromal cell cultures.
These results are seen in Fig. 6. The inhibitory effect was first verified by examining the
expression of osteocalcin, which is used as the marker of terminal osteogenic differentiation.
At three days after ablation, there were no differences observed between the PBS and NT virus
injected tissues, but even at this early time point there was a small decrease in osteocalcin
expression in the BMP2 shRNA lentiviral injected tissues. By seven days post injection, levels
of osteocalcin expression had risen significantly (2 to 2.5 fold) in both PBS and the NT virus
injected tissues, but showed statistically less expression than either of these controls in BMP2
shRNA lentiviral injected tissues. Examination of the various transcription factors produced a
more complex but similar set of expression data as was seen for the marrow stromal cells. Both
osterix and Runx2 showed almost no differences in their expression at day three after surgery
but both these genes showed significantly 50-75% lower levels of expression at seven days. In
contrast, Sox9 expression showed almost 2 fold greater expression in the BMP2 shRNA treated
samples at day three than either control but then showed a dramatic decrease in expression
relative to either the PBS or NT virus controls, which showed a continued increase in Sox9
expression throughout the seven day post surgical treatment period. Interestingly, Msx2
showed a significant increase in the day seven treated samples suggesting that the cells had not
progressed past their initial stages of differentiation.
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While the mRNA expression data present an average of the activity of all of the cells these
data do not directly examine the activities in individual cells. The last set of studies that are
presented directly examined the nature of the cell populations that were recruited into the
marrow space three days after ablation. Immunohistological localization using either an
antibody to Sox9 that will identify the progenitor cells that are committed to the skeletogenic
lineage [21,26] or CD146 [27], which interacts with a cell surface marker found of the
population stem cells that gives rise to the osteogenic progenitors. However, the direct
correlation between CD146 and Sox9 cells has not been established yet. These results are seen
in Fig. 7. Unlike the distinct histological differences seen at day 7 between the three
experimental groups, the day three specimens all had similar histological features showing a
dense mass of cells filling the marrow space. Comparable numbers of cells showing similar
morphologies were interspersed uniformly throughout the marrow space (Fig. 7A). Both
antibodies qualitatively appeared to recognize a small percentage of the cells in the reamed
marrow space with the Sox 9 antibody appearing to react with more cells. These
immunopositive cells appeared to be uniformly interspersed throughout the cell population
filling the space, and both antibodies recognized smaller rounded cells with the same general
morphology. The specificity of Sox9 staining was corroborated by the intense levels of reaction
seen in the growth plates of the same specimens (seen as an inset) and its strong immunostaining
of the nucleus and control non immune antibodies showed no specificity to the intramedullary
cell population (data not shown). It is interesting to note that the shBMP2 lentiviral treated
specimens all appeared to have the greatest number and intensity of Sox9 reactive cells,
consistent with the mRNA expression data seen in Fig. 6 that also showed that this mRNA was
expressed at its highest levels of expression in the BMP2 animal group (Fig. 7A).
In order to quantify the number of osteogenic stem cells found in the marrow space three days
after ablation, FACs analysis was carried out using CD146 (Fig. 7B and 7C). These analysis
showed no effect due to loss of endogenous BMP2 on the CD146 cells population after 3 days
in the cells flushed from the medullary space with a range of 0.02 to 0.1% of the cells for all
three experimental groups being positive. In the mice injected with PBS or non target shRNA
an average of 0.06 percent positive cells were recovered whereas in BMP2 shRNA treated
groups showed an average of 0.07%. The average number of cells sorted from three
independent experiments showed a very small but statistically significant increase in CD146
population in BMP2 shRNA virus injected group compared to PBS and non-target shRNA. In
summary, these data provide corroborating data to the mRNA analysis from both the cultured
marrow stromal and the marrow ablation tissues that supports the conclusion that loss of BMP2
expression does not effect the recruitment of skeletogenic stem cells, but rather promotes the
differentiation and expansion of these cells.
Discussion
Previous studies from our laboratory have shown that either the BMP antagonist noggin or
BMP2 antibody blockade inhibited osteogenic differentiation of marrow stromal cells, while
exogenously added BMP2 or BMP7 induced the endogenous expression of multiple BMPs
and enhanced their osteogenic differentiation [16]. Because the exogenous addition of BMPs
can not be used to rescue either noggin treatment or BMP2 antibody blockade, these methods
of BMP2 inhibition can not isolate the effects of one BMP from another. Nor do these methods
of BMP inhibition allow for the isolation of separate molecular effects that these different
BMPs may have since both stimulate the expression endogenously produced BMPs by the
marrow stromal cells. Recently it has been shown that both BMP7 and BMP2 regulate marrow
stromal cell osteoblastic differentiation through different receptors such that BMP2/4 used
predominantly BMPR1A whereas ACVR1A was the preferred type I for BMP-6/7 [30]. Thus,
it remains unresolved whether different BMP isotypes have differential effects on the
osteogenic differentiation of marrow stromal cells.
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Use of shRNAs to block only BMP2 expression corroborated our previous findings regarding
the central regulation of osteogenic differentiation by BMP2 while at the same time allowing
us to demonstrate that BMP2 and BMP7 do not have identical effects on osteogenic
differentiation. Thus, while both BMP2 and BMP7 equally promoted the expression of osterix,
and the development of equal numbers of osteogenic nodules, the exogenous addition of BMP7
to the BMP2 shRNA-treated cultures could not fully rescue APase activity, mineral
accumulation or the expression of Runx2. In contrast, exogenous BMP2 treatment of the BMP2
shRNA treated cultures did restore both Runx2 expression and total mineral accumulation.
This finding is consistent with several studies that have shown that BMP2 signaling both
requires and synergizes Runx2 activity to achieve maximal osteogenic differentiation in either
C2C12 or C3H10T1/2 pluripotent mesenchymal precursor cell lines [31-33]. Furthermore,
studies by Lee et al., 2001 [34], showed that BMP2 upregulated the expression of Runx2.
Therefore, the additional effects of BMP2 compared to BMP7 on MSC osteogenic
differentiation appear to be due to the direct effects that BMP2 has on Runx2 expression, while
BMP7 does not appear to regulate Runx2 expression. Interestingly, in the control cultures in
which BMP2 was not inhibited, BMP7 equally promoted osteogenic differentiation compared
to BMP2 and our data suggest that this effect is due to upregulation of BMP2. Thus these subtle
differences can only be seen when the endogenous stimulation of BMP2 expression was
removed from the system by the BMP2 shRNA treatment.
The observation that BMP7, in the absence of BMP2 signaling, could partially promote
osteogenic differentiation through the induction of osterix suggests a number of important
implications. First, osterix can independently regulate specific aspects of osteogenesis
independent of Runx2, even though osterix is induced by Runx2 and has been localized by
genetic studies to be downstream to Runx2 in the cascade of transcriptional events that control
embryonic skeletogenic development [28]. Second, BMP7 and BMP2 must have divergent or
preferential signal transduction mechanisms that separately mediate some of their nuclear
effects. In this regard, it is noteworthy that BMP2 and BMP7 appear to be part of two
structurally different subgroups of the BMP superfamily with BMP2 and BMP4 forming one
group and BMP5, BMP6, BMP7, and BMP8a/b forming the other [35]. Thus, while BMP2,
BMP4, BMP5, BMP6, and BMP7 can utilize the same type I (Alk2, Alk3, and Alk6) and type
II (ActRII, and ActRIIb) receptors [36] and can direct phosphorylation of the same set of BMP
receptor-specific second signals (Smads 1, 5, or 8) [37-40], there are differences in the
specificity of receptor binding which appear to discriminate between these two subgroups of
ligands [30]. In studies by ten Dijke et al., 1994 [41], BMP4 was shown to bind to BMPR-1A
but not Alk2, while BMP7 showed exactly the opposite specificity. Subsequent studies of
Ebisawa et al., 1999 [35], confirmed these findings and showed that there were differences in
both the combinations of BMP receptors that the various osteogenic and osteogenic progenitor
cell lines expressed as well as differences in specificity of binding of BMP2 or BMP6 to the
complement of receptors found in these different cell lines. Neither of these studies, however,
investigated the down stream consequences of this differential receptor binding.
Finally, it is important to consider that the individual BMPs may synergize in a differential
manner with other growth factors. In this regard, a number of studies have shown that IGF will
enhance the osteogenic activities of both BMP7 and BMP2 [42-44]. In the studies of Celil et
al., 2005 [42], IGF was shown to independently upregulate osterix separate from BMP2 and
that the combination of BMP2 and IGF synergistically enhanced osteogenesis and MSC
extracellular matrix mineralization. These studies further showed that while MAP kinase
inhibition blocked both IGF and BMP2 induction of osterix and decreased matrix
mineralization, that MAP kinase inhibition did not block Runx2 expression. These studies then
clearly showed a dissociation of osterix regulation from Runx2 and suggested that in the context
of our observations that BMP7’s activities are driven in part through the induction of BMP2
through its upregulation Runx2 expression.
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As noted above, one aspect of BMP function that has not been extensively studied relates to
the influence of these molecules at specific stages during cellular lineage progression. In the
current study, two separate approaches were used to determine the lineage stage at which BMP2
acts. In one approach, we used the expression levels of four transcription factors (Sox9, Msx2,
Runx2, and osterix) that have been shown to be lineage determinants for the progression of
skeletogenic cells towards their terminal osteogenic state. Sox9 was examined because all
osteo-chondroprogenitor cells, as well as lineage progenitors in a variety of tissues during
mouse embryogenesis, express Sox9 [45]. Msx2, Runx2, and osterix, respectively, have been
shown to be determinants that affect osteoblastic differentiation from the common Sox 9
expressing progenitor [28;45-48]. For the in vivo studies, an immunohistological approach was
also used. Measurement of Sox9 protein expression by immunohistological means
corroborated the molecular findings while staining for CD146 positive cells in the
intramedullary space was used as an independent means of identifying the osteoprogenitor
population. This marker was shown in recent studies in human marrow stromal cell populations
to identify the self renewing osteogenic stem cell population in the bone marrow space and
these studies showed that human CD146 positive cells isolated from the bone marrow were
both self renewing formed bone upon transplantation into an ectopic site, as well as support
the development of a hematopoietic microenvironment [27]. In the context of the studies
reported here, cells expressing this surface maker remained unaffected by BMP2 shRNA
treatment and even showed a small increase in their numbers, which was consistent with our
interpretation of the data related to the transcriptional factors as lineage stage determinants.
These vivo results suggest that BMP2 does not act to expand stem cell numbers based on the
expression of Sox9 and CD146, but rather that the target stage of its actions is at the level later
than the committed chondro/osteo bipotential cell. Indeed BMP2, when added back to the
shRNA-treated cultures, showed that the levels of Sox9 decreased slightly. It is interesting to
note the differences in the comparison to BMP7 in that BMP7 rescue in BMP2 shRNA-treated
cultures appeared to increase the expression of Sox9 suggesting that BMP7 might play a role
in expanding the progenitor cell population. In this context, the differences in the effects of
BMP2 and BMP7 on Runx2 expression may also play a role since increased Runx2 expression
is reciprocally and mechanistically related to decreased proliferation and terminal commitment
of the osteoprogenitors to their terminal state of differentiation [48].
These in vitro results were confirmed by the in vivo comparisons at three days after bone
marrow ablation when the expression levels of Sox9 mRNA and the observed number of both
Sox9 and CD146 immunopositive progenitors was actually greater or equal in both control and
BMP2 shRNA-treated cell populations. However, differences between in vitro and in vivo
results were observed at the later time points in that Sox9 levels along with those for Runx2
and osterix were dramatically inhibited in contrast to the levels of Msx2 which were greatly
increased. While these results are inconsistent with our interpretation that BMP2 does not affect
the recruitment of osteoblast progenitors, we interpret the diminished levels of mRNA
expression at seven days to reflect either the failure of the progenitors to survive or an alternate
stage of differentiation that expresses a phenotype that no longer expresses Sox9. This later
interpretation would be consistent with the very large increase in levels of Msx2, the fact that
expression Msx2 expression was associated with the prevention of osteoblastic differentiation
and mineralization of the extracellular matrix whereas, antisense Msx2 RNA decreased
proliferation and accelerated differentiation [29].
In summary, these results suggest that BMP2 acts after the stage of osteoprogenitor recruitment
and primarily drives bone marrow stem cells towards terminal osteoblastic differentiation.
BMP7, in the absence of BMP2, appears to increase the numbers of progenitors but is less
efficient at promoting terminal differentiation. This primary difference in the effects of these
two BMPs appears to be related to their differential actions on Runx2 and osterix expression.
Three recent animal studies reported clinically-relevant findings that are potentially consistent
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with the findings and mechanisms that we suggest here. In one study, the co-administration of
adenovirus-mediated gene transfer for both BMP2 and BMP7 showed comparatively more
stable spinal fusion and higher levels of mineralization compared to the single, individual
transfer of either BMP [50]. In the second study, a delay in the timing of injection of the
adenoviral BMP2 expression vector until 5 or 10 days after surgery increased the percentage
of critical-sized segmental defects that achieved radiological union and showed enhanced
mineralization and greater mechanical strength [51]. In the third study, using a non human
primate critical size defect model showed that delaying BMP2 treatment for up to one week
after surgery gave the optimal therapeutic effects. These authors concluded that the accelerated
healing seen in the delayed treatment groups was because of an increase in the number of
responding cells that came into the surgical site which were then responsive to BMP2, which
increased direct bone formation [52]. These observations, as well as recent clinical experiences
in which recombinant human BMPs 2 and 7 (Osteogenic Protein 1; OP-1) showed less than
consistent results in achieving fracture union suggest that a deeper understanding of their how
BMPs act on specific stages of the osteogenic lineage may be required for more successful
therapeutic application.[53]
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Fig. 1. Characterization of Marrow Stromal Culture Transduction with Lentiviral BMP2 shRNA
Expression Constructs
C= control no virus transduction and NT= transduced with non target virus. A) Assessment of
the optimal multiplicity of infection (MOI) for lentiviral transduction by green fluorescent
protein expression. Viral titers are as indicated in the figure. Representative phase contrast
microscopy images taken under UV light excitation are depicted (100X magnification).
Percentage optimal cell transduction was validated by FACs analysis. B) Effect of lentiviral
transduction on cellar viability after 21days of culture growth. Viability was measured by LDH
enzyme release as quantified by OD405nm showed no significant difference. . C) Effect of
lentiviral transduction on formation of alizarin red stained osteogenic nodules. Representative
images are of mineralized nodule formation in triplicate 33mm culture wells after 21 days of
growth in mineralization media. D) Identification of the optimal BMP2 shRNA for BMP2
RNA silencing in MSC cultures. Cultures were separately transduced three different lentiviral
constructs each containing a unique shRNA to BMP2. The expression of BMP2 mRNAs are
Bais et al. Page 16
Bone. Author manuscript; available in PMC 2010 August 1.
presented as the relative value to NT transduced cultures. Values were determined at 21 days
in culture. Numeric notation of the separate lentivirus constructs are as provided by Sigma
Aldrich Corporation from The MISSION shRNA library of The RNAi Consortium. E)
Functional effect of the various BMP2 shRNAs on osteocalcin mRNA expression relative to
NT transduced cultures was determined at 21 days. F) Functional effect of effect of various
BMP-2 shRNA on alkaline phospatase (Apase) activity. Activities were assessed at multiple
time points as indicated in the figure. Lentivirus BMP2 shRNA clone 878 showed significant
down regulation of BMP2 mRNA, osteocalcin mRNA and APase activity. Error bars represent
standard deviation from replicates measurements from three experiments. P-value reflects the
comparison of different treatment groups calculated by t-test and denoted as * p<0.05, **
p<0.01.
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Fig. 2. Rescue of Osteogenic Differentiation with Exogenous Addition of BMP7 in BMP2 shRNA
Treated MSCs
NT= cultures transduced with non targeted; BMP7= transduced with NT lentivirus and treated
with 200ng/ml BMP7; shBMP2= cultures transduced with lentivirus containing BMP2
shRNA; and Rescued= cultures transduced with lentivirus containing BMP2 shRNA and
treated with 200ng/ml BMP7. All RNA measurements made from three separate preparations
of cells and error bars are the SD of the triplicate measurements from 3 separate cell
preparations. A) Steady state BMP2 mRNA expression levels over the time course of in vitro
osteogenic differentiation. RNA measurements are presented as a relative fold of expression
to day 1. B) Steady state BMP2 mRNA expression levels after 21 days growth in cultures under
various experimental conditions. RNA measurements are presented as a relative value to the
NT control. C) APase activities were assessed at 21 days time points. Error bars are the SD
from three separate cell culture preparations. D) Representative images of mineralized nodule
formation in triplicate 33mm culture wells after 21 days of growth in mineralization media.
E) Quantification of effect of lentiviral transduction on Ca++ accumulation. Calcium bound
alizarin dye was released as described in the materials and absorbance was analyzed. F) Effect
of lentiviral transduction on formation of Alizarin red stained nodules. Error bars represent
standard deviation from replicates measurements from three experiments. P-value reflects the
comparison of different treatment groups calculated by t-test and denoted as * p<0.05, **
p<0.01, *** p<0.001.
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Fig. 3. Effect of Exogenous Addition of BMP7 in BMP2 shRNA Treated MSCs on the Expression
of Various Transcription Factors that Control Skeletal Stem Cell Lineage Progression
The nature of each mRNA that was assayed is indicated in the figure. Left panels in the figure
present the steady state mRNA expression levels of the various transcription factors over the
time course of in vitro osteogenic differentiation. RNA measurements are presented as a
relative fold of expression to day 1. Right panels show the transcription factor mRNA
expression levels after 21 days growth in cultures under various experimental conditions. RNA
measurements are presented as a relative value to the NT control. Mean values are
measurements made from three separate preparations of cells. Error bars represent standard
deviation from replicates measurements from three experiments. P-value reflects the
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comparison of different treatment groups calculated by t-test and denoted as * p<0.05, **
p<0.01, *** p<0.001.
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Fig. 4. Affect of Exogenous Addition of BMP2 on BMP2 shRNA Treated Culture
All data is presented as the fold of the control untreated MSC cultures at 21 days. A) The
exogenous addition of BMP2 protein rescue of nodule and mineral deposition in BMP2 shRNA
inhibited MSCs cultures. Left panel shows the fold change in BMP2 mRNA expression in
response to both BMP2 shRNA treated and BMP2 shRNA in the presence of exogenous
addition of BMP2. Right panel shows the total mineral accumulation as measured by alizarin
dye uptake by BMP2 rescue in comparison of NT shRNA and NT shRNA with BMP2 protein.
B) Affect of Exogenous Addition of BMP2 in BMP2 shRNA Treated MSCs on the Expression
of Various Transcription Factors that Control Skeletal Stem Cell Lineage Progression. Error
bars represent standard deviation from replicate measurements from three separate cell
preparations. P-value reflects the comparison of different treatment groups calculated by t-test
and denoted as * p<0.05, ** p<0.01, *** p<0.001.
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Fig. 5. In vivo Effects of BMP2 shRNA Inhibition on Bone Formation after Marrow Ablation
A) Gross staining of tibiae to detect β-galactosidase activity. Individual tibia from mice injected
with either PBS control or lentiviral particles that expression β-galactosidase. Representative
images of three bones that had been cut in half and reacted with X-gal staining are shown.
Staining is detected as dark green to green brown areas and is denoted with arrows. B)
Representative in vivo measurements of bioluminescent intensities from mice injected with
lentivirus overexpressing luciferase (lenti-Luc) compared to PBS injected controls. The data
are reported as the photon flux (p/s) from a defined region of interest in tibia of lentivirus
expressing luciferase compared to noninjected control mice. C) MicroCT assessment of
endosteal bone formation in response to surgical marrow ablation. All images are orientated
with the proximal end of the bone at the top and are from 7 days after the time of surgery.
Representative μCT 3D renderings of bone formation from control mice and mice injected
with NT and BMP2 shRNA lentiviral particles are shown in the top panels. Graphical
measurements of percent bone tissue (BV/TV) as determined from the μCT analysis are
presented in the below the microCT images. The Comparisons for all pairs using one way
ANOVA showed statistically significant difference in mean in shBMP2 group (mean=0.66)
compared to PBS (Mean =0.14) and NT (mean= 0.10) and p value<.0001 denoted as
***showing significant differences in each group. Analysis by t-test showed also showed
significance for the comparison of shBMP2 with p <.05 whereas with PBS p<.0001. D)
Histological Analysis of bone formation in response to surgical marrow ablation. All images
are orientated with the proximal end of the bone at the right side of the micrographs. Sections
were cut in longitudinal orientations and sections were selected from the central regions such
that the surrounding cortices are seen. Sections were stained with H&E. In shRNA injected
groups, there is observable loss of trabecular structure and bone loss indicated by arrow.
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Fig. 6. Effect of BMP2 shRNA Lentiviral Treatment on the Expression of Various Transcription
Factors that Control Skeletal Stem Cell Lineage Progression within Bone Tissues Formed After
Surgical Ablation
Individual samples are as denoted in the figure and the legend. Levels of expression are relative
to unoperated control tibia bones. Error bars represent standard deviation from replicates
measurements from three experiments. P-value reflects the comparison of different treatment
groups calculated by t-test and denoted as * p<0.05, ** p<0.01, *** p<0.001.
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Fig. 7. Effect of BMP2 shRNA Lentiviral Treatment on the Development of Immunoreactive Cells
Showing Stem Cell and Osteogenic Progenitor Marker Expression
A) Immunohistology of CD146 and Sox9 reactive cells. Tibiae were collected three days post
bone marrow ablation. Tissues were cut in longitudinal orientations and sections were selected
from the central regions. Sections were reacted with antibodies directed against mouse specific
CD146 or Sox9. All photomicrographs were taken at 200X magnification. Immunopositive
cells stain reddish brown. The experimental group and antibody used for the immunostaining
are indicated in the figure. The inset in left lower (PBS/Sox9) image depicts positive
immunostaining for Sox 9 in the growth plate from the same specimen. B) Quantification of
CD146 positive osteoprogenitor stems cells in different treatment groups. Representative FACs
analysis of CD146 positive cells observed in the total population of cells flushed from the
marrow space three days post surgery and plated overnight before FACs. The gated population
was optimized for nonspecific stating by isotype control antibody. Left Panel Shows 0.06%
CD146 positive cells in gate R4 from tibia of mice injected with PBS as a control. Middle panel
shows this cell population in nontarget shRNA treated group (006%). Right panel shows that
the BMP2 shRNA treatment produced a slight increase in CD146 cells (0.07%). The total
number of CD146 cells sorted cells from three separate experiments plotted, showed statistical
significant difference in shRNA treated groups compared to PBS (p= 0.00154) and NT
(0.028139). Error bars are standard deviation from replicates measurements from three
experiments. P-value reflects the comparison of different treatment groups calculated by t-test
and denoted as * p<0.05, ** p<0.01, *** p<0.001.
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